companies alkermes-plc 
IP Law 360
AUGUST 7, 2023
in its dispute with Alkermes PLC over a multiple sclerosis drug, but refused to increase the award by $65.6 million to refund the company for royalties paid after the drug's patent expired. A New York federal judge has confirmed a nearly $16.6 million arbitral award issued to Acorda Therapeutics Inc.
IP Law 360
JUNE 6, 2023
Biopharmaceutical company Alkermes PLC on Tuesday boosted its financial forecast for 2023 by $425 million after the company said it wrapped arbitration proceedings with Johnson & Johnson subsidiary Janssen Pharmaceutica NV over two license agreements for small particle pharmaceutical compound technology that Janssen uses in antipsychotic, schizophrenia (..)
IP Law 360
APRIL 20, 2022
Biopharmaceutical company Alkermes PLC said it has entered binding arbitration with Johnson & Johnson subsidiary Janssen Pharmaceutica NV over two licensing agreements for small particle pharmaceutical compound technology Janssen uses in antipsychotic, schizophrenia and HIV drugs.
Expert insights. Personalized for you.
40 
Let's personalize your content